User:Shh57171/Dopamine agonist/Pndakip Peer Review: Difference between revisions

From Wikipedia, the free encyclopedia

Content deleted Content added


Latest revision as of 15:18, 15 October 2025

Whose work are you reviewing?

(provide username)

Link to draft you’re reviewing
Link to the current version of the article (if it exists)

Evaluate the drafted changes

[edit]

I like your proposed changes! I agree with you that there shouldn’t be an overview of pharmacodynamics, maybe a one sentence description and a link to the main wiki page for pharmacodynamics would be more suitable.

I also agree with you that the medical uses section should be more expanded. It felt like the article kept on only referencing Parkinson’s disease treatments throughout, which made the article sound like a Parkinson’s disease article rather than a dopamine agonist one. I think just being able to link what the paper talks about with other drugs and diseases would benefit the article a lot.

If you are can find some, maybe some papers describing general trends that all dopamine agonists share would be beneficial so that the paper doesn’t feel like a large summary of a lot of different drugs without a link between them. For example, why are do “Dopamine agonists have two subclasses: ergoline and non-ergoline agonists”? I feel like this could be a in the intro header or section in itself instead of within the subsection of Parkinson’s disease without an explanation of the theory behind it. Also, something you could add is a very short definition of what an agonist is, since it is very relevant to the article topic, and might help readers understand the article better.

I agree with you that there is a lot of information repeated, and I think a bit of a clean up would help this article a lot. I like your sources and proposed changes, and I think you’re off to a really good start!

Leave a Comment

Your email address will not be published. Required fields are marked *

Exit mobile version